Acute Ischemic Stroke
Conditions
Interventions
treatment group:Intravenous drop NBP Injection 25mg(100ml) at least 50 to 70 minutes each time and twice daily, at least 6 hours interval of between two drops, at least 14 days. From day 15 to day 90,
control group:Intravenous drop Blank NBP Injection 100ml every time, oral placebo butyl phthalide soft capsule. Others same as experimental group.
Sponsors
Department of Neurology, Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Onset within 48 hours of the internal carotid system cerebral infarction; 2. First attack 3. Patients aged 35 to 75 years of age; 4. There are clear signs of nervous system orientation, neurological deficit NIHSS score was 6 to 25 hours; 5. Before the start of the study, the patient or his legal representative has signed the "informed consent."
Exclusion criteria
Exclusion criteria: 1. CT head diseases seen in intracranial hemorrhage: cerebral hemorrhagesubarachnoid hemorrhage, etc.; 2. Awareness of severe obstacles: NIHSS level of awareness of the project 1a> 1 patient; 3. ischemic attack (TIA) 4. The patients who have been treated with thrombolysis and stent procedure ; 5. With severe hypertension: systolic blood pressure >=200mmHg (26.6kPa) or diastolic blood pressure >= 110mmHg (14.6kPa); 6. Tendency to suffer from hemorrhagic disease; 7. Liver dysfunction (transaminases more than 1.5 times the upper limit of normal), renal dysfunction (Cre> 2.0mg/dl or 177umol/L), cardiac dysfunction or suffering from other serious systemic diseases, such as; 8. Concurrent malignancy or ongoing anti-tumor treatment; 9. Past of celery,study drug and control history of drug allergy or those who can not be tolerated; 10. Pregnancy, lactation or pregnancy and planned pregnancy may be the patients; 11. Achieved in the prior informed consent within 3 months of participation in other clinical research, or are participating in other clinical stu dies; 12. Researchers think that is not suitable to participate in this clinical study of patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of Rankin scales (MRS);NIHSS score;EQ-5D; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stroke mortality and recurrence rate; | — |
Countries
China
Contacts
Public ContactCui LiYing
Outcome results
None listed